skin cancer Castle Biosciences Receives NYS DOH Approval for Skin Cancer Diagnostic The company's DecisionDx-SCC is meant to predict risk of cutaneous squamous cell carcinoma metastasis for patients with one or more risk factors. Castle Biosciences to Expand Range of Dermatology Diagnostics Beyond Cancer Premium The company said it is developing a new genomic test to predict therapeutic response in patients with inflammatory skin conditions. Castle Biosciences Q1 Revenues Up 31 Percent The company said it delivered 11 percent fewer DecisionDx-Melanoma test results year over year, but that the total number of all tests delivered rose 4 percent. Eye Color GWAS Leads to 50 New Loci, Underscoring Trait's Complexity A genome-wide association study in almost 193,000 Europeans led to 61 eye color-related loci, some of which also influence iris pigmentation of Asian individuals. Castle Biosciences Q4 Revenues Down 2 Percent The skin cancer diagnostics company said it delivered 5 percent fewer DecisionDx-Melanoma test results in Q4 2020 than in the previous year's fourth quarter. Mar 5, 2021 DermTech Q4 Revenues Up 31 Percent Feb 16, 2021 Circulating Tumor DNA Provides Prognostic Clues in Advanced BRAF-Mutated Melanoma Cases Feb 12, 2021 DermTech Enters Agreement With Blue Cross Blue Shield of Texas for Skin Cancer Assay Jan 7, 2021 DermTech Prices $125M Public Offering of Common Stock Jun 22, 2020 Genomic Study Reveals Recurrent Cutaneous Melanoma Alterations, Male-Specific Mutations Jun 5, 2020 Secondary Tumor Risk in Pediatric Cancer Survivors Linked to Germline Variants, Treatment Type Apr 27, 2020 Cutaneous Melanoma Clues Found From Risky SNPs, Related Traits Analyses Mar 9, 2020 DermTech Trying to Drum up Payor Coverage for Melanoma Test With Study Results Premium Nov 11, 2019 Castle Biosciences Q3 2019 Revenues Quadruple Sep 24, 2019 SkylineDx Partners With Mayo Clinic on Melanoma Risk Test Study Ahead of Planned US Trial Premium Sep 16, 2019 Australian Skin Cancer Genetic Study Seeks to Recruit 20K Additional Participants Sep 3, 2019 Castle Biosciences Q2 Revenues Up 168 Percent Jul 25, 2019 Castle Bio Prices IPO at $16 per Share Mar 7, 2019 Mutagenic Processes in Cancer Cell Lines Can Be Persistent, Episodic Oct 22, 2018 GeneATLAS Database Documents Diverse Trait Associations Detected With UK Biobank Data Oct 4, 2018 Geneseq, Australian Clinical Labs Partner to Commercialize Melanoma Test Aug 22, 2018 APOBEC-Linked Mutational Signatures Drive Skin Cancer in Recessive Dystrophic Epidermolysis Bullosa May 8, 2018 Skin Tanning Tied to 20 Genetic Loci in Large European GWAS Feb 21, 2018 New York State Accredits DermTech Jan 4, 2018 Chromatin Remodeling Mutations Linked to Immunotherapy Response Load More Breaking News Roche Receives EUA for PCR-Based, Point-of-Care SARS-CoV-2 Test Decode Study Identifies Proteomic Predictors of All-Cause Mortality In Brief This Week: Natera, Bruker, Bayer, and More New Products Posted to GenomeWeb: Labcorp, Omniseq, Dovetail Genomics, DNA Script, More People in the News: New Appointments at Sema4, Strata Oncology, Bionano Genomics, More Co-Diagnostics Gets CE Mark for Saliva-Based Molecular SARS-CoV-2 Test The Scan Billions for Antivirals The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports. NFT of the Web Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports. 23andMe on the Nasdaq 23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported. Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.